All In Biotech

Drug Trial Radar · NCT04478513

A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

A Phase I, Open-label, Non-randomised Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor) and Smoking (CYP1A2 Inducer) on the Pharmacokinetics of a Single Oral Dosing of AZD4635 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Jul 21, 2020

Primary completion

Dec 23, 2020

Study completion Dec 23, 2020

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase I, open-label, non-randomized, 2-period, fixed-sequence study in healthy volunteers who are either smokers or non-smokers, performed at a single Clinical Unit.

Conditions

  • Healthy Volunteer/DDI Study

Interventions

  • AZD4635Drug

    During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.

  • FluvoxamineDrug

    Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve from time zero to infinity (AUC)Time frame: Days 1-6 and Days 11-16
  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)Time frame: Days 1-6 and Days 11-16
  3. Maximum observed plasma concentration (Cmax)Time frame: Days 1-6 and Days 11-16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.